0
     

Report Added
Report already added
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Biliary Cholangitis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Primary Biliary Cholangitis (Other Diseases) pipeline landscape.

Primary biliary cirrhosis is a chronic disease of the liver that slowly destroys the bile ducts within the liver. Symptoms include fatigue, itchy skin, dry eyes, jaundice, swollen feet and ankles, pain in the upper right portion of the abdomen and diarrhea. Predisposing factors include age and history of infections. Treatment includes bile acid sequestrants and liver transplantation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Biliary Cholangitis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Primary Biliary Cholangitis (Other Diseases), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Biliary Cholangitis (Other Diseases) pipeline guide also reviews of key players involved in therapeutic development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 9, 4, 1, 9, 4 and 1 respectively.

Primary Biliary Cholangitis (Other Diseases) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Biliary Cholangitis (Other Diseases).
- The pipeline guide reviews pipeline therapeutics for Primary Biliary Cholangitis (Other Diseases) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Primary Biliary Cholangitis (Other Diseases) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Primary Biliary Cholangitis (Other Diseases) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Primary Biliary Cholangitis (Other Diseases)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Primary Biliary Cholangitis (Other Diseases).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Primary Biliary Cholangitis (Other Diseases) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Overview
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Companies Involved in Therapeutics Development
AbbVie Inc
Abcuro Inc
Albireo Pharma Inc
Alexion Pharmaceuticals Inc
Ascletis Pharma Inc
Avolynt Inc
Calliditas Therapeutics AB
CAMP4 Therapeutics Corp
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Cour Pharmaceuticals Development Co Inc
CymaBay Therapeutics Inc
Dr. Falk Pharma GmbH
Escient Pharmaceuticals Inc
Future Medicine Co Ltd
Genfit SA
GenKyoTex SA
GentiBio Inc
Gilead Sciences Inc
Hanmi Pharmaceuticals Co Ltd
HighTide Therapeutics Inc
Kissei Pharmaceutical Co Ltd
Kowa Co Ltd
MediGene AG
Mirum Pharmaceuticals Inc
NGM Biopharmaceuticals Inc
Parvus Therapeutics Inc
PRISM Pharma Co Ltd
Selecta Biosciences Inc
Shaanxi Micot Technology Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Umecrine Cognition AB
Zydus Lifesciences Ltd
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Drug Profiles
A-3907 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ABC-008 - Drug Profile
Product Description
Mechanism Of Action
aldafermin - Drug Profile
Product Description
Mechanism Of Action
History of Events
ASC-42 - Drug Profile
Product Description
Mechanism Of Action
AVO-1681 - Drug Profile
Product Description
Mechanism Of Action
bezafibrate SR - Drug Profile
Product Description
Mechanism Of Action
History of Events
budesonide DR - Drug Profile
Product Description
Mechanism Of Action
History of Events
bulevirtide - Drug Profile
Product Description
Mechanism Of Action
CNP-104 - Drug Profile
Product Description
Mechanism Of Action
History of Events
elafibranor - Drug Profile
Product Description
Mechanism Of Action
History of Events
EP-547 - Drug Profile
Product Description
Mechanism Of Action
History of Events
golexanolone - Drug Profile
Product Description
Mechanism Of Action
History of Events
HM-15211 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HTD-1801 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LJ-2698 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MT-2004 - Drug Profile
Product Description
Mechanism Of Action
norursodeoxycholic acid - Drug Profile
Product Description
Mechanism Of Action
Oligonucleotides for Primary Biliary Cholangitis - Drug Profile
Product Description
Mechanism Of Action
pemafibrate - Drug Profile
Product Description
Mechanism Of Action
PRI-724 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Primary biliary cholangitis - Drug Profile
Product Description
Mechanism Of Action
Primary Biliary Cholangitis (PBC) - Drug Profile
Product Description
Mechanism Of Action
History of Events
PVT-201 - Drug Profile
Product Description
Mechanism Of Action
remogliflozin etabonate - Drug Profile
Product Description
Mechanism Of Action
History of Events
RhuDex - Drug Profile
Product Description
Mechanism Of Action
History of Events
saroglitazar - Drug Profile
Product Description
Mechanism Of Action
History of Events
seladelpar lysine - Drug Profile
Product Description
Mechanism Of Action
History of Events
setanaxib - Drug Profile
Product Description
Mechanism Of Action
History of Events
tiomolibdate choline - Drug Profile
Product Description
Mechanism Of Action
History of Events
TQA-3526 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ursodiol - Drug Profile
Product Description
Mechanism Of Action
History of Events
volixibat potassium - Drug Profile
Product Description
Mechanism Of Action
History of Events
ZG-5266 - Drug Profile
Product Description
Mechanism Of Action
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Dormant Projects
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Discontinued Products
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Product Development Milestones
Featured News & Press Releases
Feb 15, 2022: First patient randomized in pivotal TRANSFORM study with setanaxib
Feb 01, 2022: Liver Institute Northwest participating in RESPONSE, a global phase 3 clinical research study evaluating an investigational therapy for the treatment of Primary Biliary Cholangitis (PBC)
Dec 10, 2021: Zydus announces EPICS-III phase 2(b)/3 adaptive pivotal clinical trial of Saroglitazar Mg in PBC
Nov 15, 2021: Gannex announces China NMPA approved phase II and III protocols of ASC42, an FXR agonist, for treatment of primary biliary cholangitis
Nov 15, 2021: CymaBay Therapeutics long-term open label study finds treatment with seladelpar for two years improves key liver biomarkers in patients with PBC
Nov 11, 2021: CymaBay Therapeutics to host post-AASLD key opinion leader webinar on seladelpar for primary biliary cholangitis
Nov 02, 2021: New clinical data on GENFIT’s investigational compound Elafibranor to be presented at AASLD The Liver Meeting
Nov 02, 2021: Pinnacle Clinical Research, PLLC participating in RESPONSE, a global phase 3 clinical research study evaluating an investigational therapy for the treatment of Primary Biliary Cholangitis (PBC)
Oct 01, 2021: CymaBay Therapeutics announces presentations at The Liver Meeting 2021
Sep 06, 2021: Gannex announces clinical trial application of ASC42, an FXR agonist, for treatment of primary biliary cholangitis accepted by China NMPA
Aug 09, 2021: Calliditas receives FDA Fast Track Designation for setanaxib in PBC
Jul 21, 2021: European Medicines Agency grants Orphan Drug Designation to Saroglitazar Mg for the treatment of patients with Primary Biliary Cholangitis (PBC)
Jun 24, 2021: Korea-US innovative bio-drug confirms the possibility of treating various rare liver diseases
Jun 23, 2021: Mirum Pharmaceuticals presents analyses from volixibat at the EASL International Liver Congress 2021
Jun 21, 2021: CymaBay Therapeutics presents positive PBC data at the International Liver Congress 2021
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by AbbVie Inc, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Abcuro Inc, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Albireo Pharma Inc, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Alexion Pharmaceuticals Inc, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Ascletis Pharma Inc, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Avolynt Inc, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Calliditas Therapeutics AB, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by CAMP4 Therapeutics Corp, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Cour Pharmaceuticals Development Co Inc, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by CymaBay Therapeutics Inc, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Dr. Falk Pharma GmbH, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Escient Pharmaceuticals Inc, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Future Medicine Co Ltd, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Genfit SA, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by GenKyoTex SA, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by GentiBio Inc, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Gilead Sciences Inc, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by HighTide Therapeutics Inc, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Kissei Pharmaceutical Co Ltd, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Kowa Co Ltd, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by MediGene AG, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Mirum Pharmaceuticals Inc, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by NGM Biopharmaceuticals Inc, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Parvus Therapeutics Inc, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by PRISM Pharma Co Ltd, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Selecta Biosciences Inc, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Shaanxi Micot Technology Co Ltd, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Umecrine Cognition AB, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Zydus Lifesciences Ltd, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Dormant Projects, 2022
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Dormant Projects, 2022 (Contd..1)
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Discontinued Products, 2022

List of Figures
Number of Products under Development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

Report Title: Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

Dental Imaging Systems: Global Markets

Dental Imaging Systems: Global Markets

Telecom operators’ strategies in the health market

Telecom operators’ strategies in the health market

China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028

China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028

2022 Vietnam Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Vietnam Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline